ClinicalTrialsFinder
RecruitingNCT07182903

Fatigue in MS: From Invisible to Measurable

Sponsor

University Medical Center Groningen

Enrollment

40 participants

Start Date

Oct 27, 2025

Study Type

OBSERVATIONAL

Conditions

Multiple Sclerosis

Summary

Fatigue is one of the most common and burdensome symptoms of MS, but its precise cause remains unknown, and an effective treatment is lacking. Previous research has shown that the progression of MS is associated with a higher presence of a specific type of T-cell, the cytotoxic CD4+ T-cells, which play a role in the immune system. The aim of this study is to investigate whether these cells can also be linked to fatigue in people with MS.

Eligibility

Min Age: 18 YearsMax Age: 60 Years

Inclusion Criteria4

  • Diagnosis of relapsing remittion, primary progressive or secondary progressive MS
  • Age: 18-60 years
  • Ability to perform the foot-tapping task
  • Ability to walk at least 20 meters (with or without walking aid)

Exclusion Criteria6

  • Dimethyl fumarate, fingolimod or alemtuzumab treatment, since these medications have a strong influence on the immune system As a result of these treatments, there are few to no immune cells circulating in the blood, meaning we cannot find our population of interest in the blood.
  • Change in medication 6 weeks before the start of the study (including medication not related to MS) - MS relapse within 6 weeks of the start of the study
  • Had an infection in the last month - Received a vaccination in the last 14 days - Pregnant or pregnancy in the last 6 months
  • Having a psychiatric disorder
  • Having a neurological disorder other than MS
  • Having cognitive or communicative problems that makes it hard to follow instructions

Locations(1)

UMCG

Groningen, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07182903

Related Trials

From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis

NCT048734921 location

Upper Limb Nerve Cryoneurolysis is Non Inferior to the Usual Care and Has Therapeutic Add Value in Dealing With Shoulder Pain and Functional Problems Caused by Spasticity and Motor Impairment

NCT067824641 location

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

NCT0381634552 locations

Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

NCT074776392 locations

Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

NCT072253611 location